ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 403

Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?

Justin Hung Tiong Tan1, Sook Fun Hoh2, Manasita Tanya1, Lena Das1, Ma Thin Mar Win3, Yiong Huak Chan3 and Thaschawee Arkachaisri1,4, 1Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 2Nursing, KK Women's and Children's Hospital, Singapore, Singapore, 3Biostatistics Unit, Yong Loo Lin School of Medicine, Singapore, Singapore, 4Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: juvenile SLE, Lupus nephritis, Nephritis, proteinuria and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The time to recovery from
proteinuria in patients with lupus nephritis (LN) receiving standard treatment
has been described in adult, but not in children. In adult, 52% recovered from
proteinuria within 2 years and 3/4 within 5 years. We aim to determine the time
to recovery from proteinuria and to identify factors predicting time to
improvement.

Methods:

Twenty-four childhood-onset lupus
nephritis (cLN) patients receiving standard treatment, were identified from our
lupus registry followed from Jan 1, 2009 to May 31, 2015. Indication for biopsy
includes persistent proteinuria ≥ 0.5 gm/day or spot protein/creatinine
ratio > 0.2. Demographic, clinical, laboratory, disease activity indices and
histological data were collected. Time to recovery from proteinuria was assessed
by Kaplan-Meier analysis. Risk factors associated with proteinuria resolution
were evaluated using cox-regression models.

Results:

Twenty-four
cLN patients (66.7% females) were recruited. Majority were Chinese (54.2%),
followed by Malays (29.2%). No
Indian patients had LN. 83.3% cLN patients presented at diagnosis. Median time
to protein clearance was 5.8 months (Fig 1). About 90% recovered from proteinuria
within 18 months. Higher SLEDAI-2K scores at diagnosis was associated with
shorter time to protein clearance. (HR 1.155, 95% CI 1.046-1.275, p=0.004). Older
age, higher chronicity index and nephrotic at baseline were associated with
longer time to protein clearance while gender, race, activity index and low
complement were not significant risk factors. (Table 2)

Conclusion:

Faster urinary protein clearance
was demonstrated in our cLN cohort receiving standard treatment compared to
that of adults (5.8 months vs 2 years) and 90% achieved in 18 months. Patients
with higher disease activity at baseline seem to respond better to treatment
with shorter time to protein clearance. Consistent with adult findings,
patients with higher level of proteinuria at baseline needed longer time to
achieve protein clearance.

 


Disclosure: J. H. T. Tan, None; S. F. Hoh, None; M. Tanya, None; L. Das, None; M. T. M. Win, None; Y. H. Chan, None; T. Arkachaisri, None.

To cite this abstract in AMA style:

Tan JHT, Hoh SF, Tanya M, Das L, Win MTM, Chan YH, Arkachaisri T. Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/proteinuria-in-childhood-onset-lupus-nephritis-when-does-it-go-away/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteinuria-in-childhood-onset-lupus-nephritis-when-does-it-go-away/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology